Convenia 10ml Injection
This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Cefovecin 80mg/ml|
|Indication||Treatment of bacterial infections in dogs and cats. Dogs. Skin infections including bacterial folliculitis, wounds and abscesses caused by susceptible strains of Staphylococcus intermedius, Streptococcus canis (Group G, β-haemolytic), E. coli and Proteus mirabilis. Adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of gingival and periodontal tissues associated with Porphyromonas sp. and Prevotella sp. Urinary tract infections (cystitis) associated with susceptible strains of E. coli, P. mirabilis and Staph. intermedius. Cats. Skin infections including abscesses and wounds caused by susceptible strains of Pasteurella multocida, Strep. canis (Group G, β-haemolytic), and Staph. intermedius. Urinary tract infections associated with susceptible strains of E. coli.|
|Contraindications||Administration to food producing species of animals or guinea pigs. Administration to dogs or cats with a known allergy to cephalosporins.|
|Actions||Microbiology Cefovecin has a broad spectrum of clinically useful antibacterial activity that includes Staphylococci, Streptococci, and Gram-negative species (including Escherichia coli). The compound is not active against most Pseudomonas sp. or Enterococci.Pharmacology Like other β-lactam antimicrobials, cefovecin exerts its inhibitory effect by interfering with bacterial cell well synthesis. This interference is primarily due to the fact that it covalently binds to the penicillin binding proteins (transpeptidase and carboxypeptidase) which are essential for synthesis of the bacterial wall. Therefore, Convenia is bactericidal.Pharmacokinetics Cefovecin is rapidly and completely absorbed following subcutaneous administration. Nonlinear kinetics are exhibited (plasma concentrations do not increase proportionally with dose). Cefovecin does not undergo hepatic metabolism and the majority of a dose is excreted unchanged in the urine. Excretion of unchanged drug in the bile is a minor route of elimination. In vitro protein binding is greater than 98% in dog and cat plasma.|
|Warnings||The safe use of Convenia in animals less than 4 months of age, pregnant animals, animals used for breeding purposes or in lactating animals has not been established. Safety has not been established for intramuscular or intravenous administration or long-term use. The safe use of this product administered concomitantly with other protein bound drugs has not been studied. Such drugs commonly used include NSAIDs, cardiac, anticonvulsant, and behavioural medications.Positive direct Coombs' test results and false positive reactions for glucose in the urine have been reported during treatment with some cephalosporin antibacterials. Transient leucopenias have been reported in humans receiving cephalosporins. Some antibacterials, including cephalosporins, can cause lowered albumin values due to interference with certain testing methods.|
|Precautions||For use only in dogs and cats when indicated by antibiotic sensitivity testing according to principles of prudent use. In penicillin allergic animals, Convenia should be used with caution.|
|Dosage and Administration||Administer as a single subcutaneous injection at a dosage of 1 mL/10 kg bodyweight (8 mg/kg). A single injection provides a full 14 day course of therapy. Skin infections in dogs. A second subcutaneous injection can be administered 14 days after the first dose to provide therapeutic levels for a total of 28 days. Factors to be considered in the determination of an additional dose are the nature and severity of the infection, the susceptibility of the pathogen, and the immune status of the animal.Susceptibility of bacterial pathogens should be determined prior to treatment. Therapy with Convenia may be initiated before the results of these tests are known. If acceptable response to treatment is not observed, then the diagnosis should be re-evaluated and appropriate alternative therapy considered. A single injection is indicated for severe infections of the gingival and periodontal tissues in dogs as an adjunct to mechanical or surgical periodontal surgery. Preparation of solution for injection. To deliver the appropriate dose, reconstitute Convenia with 10 mL Sterile Water for Injection, USP. Shake and/or allow vial to sit until all material is dissolved.|
|Storage||Store at 2 to 8°C. (Refrigerate. Do not freeze.) Protect from light.|
|MSDS (external link)||Not specified|
|Label (external link)||Convenia Label|
|Manufacturer||Zoetis Australia Pty Ltd|